Repros Therapeutics Inc  

(Public, NASDAQ:RPRX)   Watch this stock  
Find more results for RPRX
Jan 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.26 - 1.33
Open     -
Vol / Avg. 0.00/611,256.00
Mkt cap 26.50M
P/E     -
Div/yield     -
EPS -0.50
Shares 39.56M
Beta 0.45
Inst. own 27%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -134.23% -114.23%
Return on average equity - -140.06%
Employees 6 -
CDP Score - -


2408 Timberloch Pl Ste B7
THE WOODLANDS, TX 77380-1021
United States - Map
+1-281-7193400 (Phone)
+1-281-7193446 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.